Publications Database

Bishop J. R. et al. (2015)

Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.

Pharmacogenetics and Genomics

November, 25(11), pp. 548-554.

Read Abstract (New Window)

Filipek P. A. et al. (2000)

The screening and diagnosis of autistic spectrum disorders

Journal of Autism and Developmental Disorders

29(6), pp. 439-484

Read Abstract (New Window)

King B. H. et al. (2001)

Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.

Journal of the American Academy of Child and Adolescent Psychiatry

40(6), pp. 658-665

Read Abstract (New Window)

Lecavalier L. et al. (2014)

Measuring anxiety as a treatment endpoint in youth with autism spectrum disorder.

Journal of Autism and Developmental Disorders

May, 44(5), pp. 1128-1143.

Read Abstract (New Window) Read Full (New Window)

Leventhal B. L. et al. (1993)

Clinical and neurochemical effects of fenfluramine in children with autism.

Journal of Neuropsychiatry and Clinical Neurosciences

5(3), pp. 307-315

Read Abstract (New Window)

Owley T. et al. (2010)

A pharmacogenetic study of escitalopram in autism spectrum disorders.

Autism Research

3(1), pp. 1-7.

Read Abstract (New Window)

Owley T. et al. (2006)

A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.

Journal of Child and Adolescent Psychopharmacology

16(5), pp. 517-552

Read Abstract (New Window)

Owley T. et al. (2005)

An open-label trial of escitalopram in pervasive developmental disorders.

Journal of the American Academy of Child and Adolescent Psychiatry

44(4), pp. 343-348

Read Abstract (New Window)

Porges S. W. et al. (2014)

Reducing auditory hypersensitivities in autistic spectrum disorder: preliminary findings evaluating the listening project protocol.

Frontier in Pediatrics

2(80),

Read Abstract (New Window) Read Full (New Window)

Riddle M. A. et al. (1999)

Anxiolytics, adrenergic agents, and naltrexone.

Journal of the American Academy of Child and Adolescent Psychiatry

38(5), pp. 546-556

Read Abstract (New Window)

Veenstra-VanderWeele J. et al.

Arbaclofen in children and adolescents with autism spectrum disorder: A randomized, controlled, phase 2 trial.

Neuropsychopharmacology

Read Abstract (New Window)